Clinical Trial Update: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CMC-544 with allogeneic transplantation for CD22-positive lymphoid malignancies has completed, with results posted in July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd22-positive B-cell Lymphoid Malignancies
• Hematologic Neoplasms
• Lymphoid Neoplasms

Drugs mentioned

• CMC-544

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-07-23